An Approach to the Treatment of Scleroderma PDF Print E-mail
Wednesday, 03 April 2013 22:30
Systemic sclerosis is unique among the rheumatic diseases because it presents the challenge of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy of small arteries that is associated with varying degrees of tissue fibrosis.

The hallmark of Scleroderma is clinical heterogeneity with subsets that vary in the degree of disease expression, organ involvement, and ultimate prognosis. Thus, the term Scleroderma is used to describe patients who have common manifestations that link them together, whereas a highly variable clinical course exists that spans from mild and subtle findings to aggressive, life-threatening multisystem disease.

The physician needs to carefully characterize each patient to understand the specific manifestations and level of disease activity to decide appropriate treatment. This is particularly important in treating a patient with Scleroderma because there is no treatment that has been proven to modify the overall disease course, although therapy that targets specific organ involvement early before irreversible damage occurs improves both quality of life and survival.

This review describes our approach as defined by evidence, expert opinion, and our experience treating patients.

Scleroderma is a multisystem disease with variable expression; thus, any treatment plan must be holistic, yet at the same time focus on the dominant organ disease. The goal of therapy is to improve quality of life by minimizing specific organ involvement and subsequent life-threatening disease. At the same time the many factors that alter daily function need to be addressed, including nutrition, pain, deconditioning, musculoskeletal disuse, comorbid conditions, and the emotional aspects of the disease, such as fear, depression, and the social withdrawal caused by disfigurement.

To read the full article, please download from the link below.

 
More articles :

» Endothelin Drugs Benefit Those With Pulmonary Hypertension

Breaking news from has reported that recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of and provides hope for treating other chronic...

» Actelion Pharmaceuticals Announces Commercial Availability Of Epoprostenol For Injection For The Treatment Of Pulmonary Arterial Hypertension

Actelion Pharmaceuticals US, Inc. today  announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and...

» Study Reveals New Genetic Link To Scleroderma

An international research consortium including scientists from T (UTHealth) has identified a new genetic link to the systemic form of . Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a...

» Development of an Activity Index for Localized Scleroderma (Morphea)

E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...

» Kidney Involvement In Scleroderma

Kidney disease is one of the manifestations of vascular, or blood vessel involvement, in .Other manifestations of vascular disease in Scleroderma include Raynaud's phenomenon, telangiectasia (dilated blood vessels, most common on the face and...

» Simple Predictor In Scleroderma Related Interstitial Lung Disease

Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.Patients classified as having “extensive” (> 20%) lung disease as...